Biologics for the Use in Chronic Spontaneous Urticaria: When and Which

被引:92
作者
Maurer, Marcus [1 ]
Khan, David A. [2 ]
Komi, Daniel Elieh Ali [3 ]
Kaplan, Allen P. [4 ]
机构
[1] Charite Univ Med Berlin, Dept Dermatol & Allergy, Dermatol Allergol, Allerg Ctr Charite, Berlin, Germany
[2] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Allergy & Immunol, Dallas, TX USA
[3] Urmia Univ Med Sci, Cellular & Mol Med Inst, Cellular & Mol Res Ctr, Orumiyeh, Iran
[4] Med Univ South Carolina, Dept Med, Charleston, SC USA
关键词
Chronic spontaneous urticaria; Angioedema; Eosinophils; Basophils; Antihistamine; Novel biologics; Anti-IgE receptor; Mast cells; Omalizumab; EPSILON-RI EXPRESSION; ANTI-SIGLEC-8; MONOCLONAL-ANTIBODY; CHRONIC IDIOPATHIC URTICARIA; CHRONIC AUTOIMMUNE URTICARIA; AFFINITY IGE RECEPTOR; HISTAMINE-RELEASE; OMALIZUMAB TREATMENT; CLINICAL-RESPONSE; SEVERE PSORIASIS; DOUBLE-BLIND;
D O I
10.1016/j.jaip.2020.11.043
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Guidelines for the treatment of chronic spontaneous urticaria (CSU) recommend the use of the IgE-targeted biologic omalizumab in patients with antihistamine-refractory disease. The rationale for this is supported by the key role of IgE and its high-affinity receptor, FceRI, in the degranulation of skin mast cells that drives the development of the signs and symptoms of CSU, itchy wheals, and angioedema. Here, we review the current understanding of the pathogenesis of CSU and its autoimmune endotypes. We describe the mechanisms of action of omalizumab, the only biologic currently approved for CSU, its efficacy and ways to improve it, biomarkers for treatment response, and strategies for its discontinuation. We provide information on the effects of the off-label use, in CSU, of biologics licensed for the treatment of other diseases, including dupilumab, benralizumab, mepolizumab, reslizumab, and secukinumab. Finally, we discuss targets for novel biologics and where we stand with their clinical development. These include IgE/ligelizumab, IgE/GI-310, thymic stromal lymphopoietin/tezepelumab, C5a receptor/avdoralimab, sialic acidebinding Ig-like lectin 8/lirentelimab, CD200R/LY3454738, and KIT/CDX-0159. Our aim is to provide updated information and guidance on the use of biologics in the treatment of patients with CSU, now and in the near future. (C) 2020 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码:1067 / 1078
页数:12
相关论文
共 132 条
[41]   Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial [J].
Hanauer, SB ;
Sandborn, WJ ;
Rutgeerts, P ;
Fedorak, RN ;
Lukas, M ;
Macintosh, D ;
Panaccione, R ;
Wolf, D ;
Pollack, P .
GASTROENTEROLOGY, 2006, 130 (02) :323-332
[42]   Comparison and interpretability of the available urticaria activity scores [J].
Hawro, T. ;
Ohanyan, T. ;
Schoepke, N. ;
Metz, M. ;
Peveling-Oberhag, A. ;
Staubach, P. ;
Maurer, M. ;
Weller, K. .
ALLERGY, 2018, 73 (01) :251-255
[43]   The Urticaria Activity Score-Validity, Reliability, and Responsiveness [J].
Hawro, Tomasz ;
Ohanyan, Tatevik ;
Schoepke, Nicole ;
Metz, Martin ;
Peveling-Oberhag, Adriane ;
Staubach, Petra ;
Maurer, Marcus ;
Weller, Karsten .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2018, 6 (04) :1185-+
[44]   Thymic Stromal Lymphopoietin Interferes with the Apoptosis of Human Skin Mast Cells by a Dual Strategy Involving STAT5/Mcl-1 and JNK/Bcl-xL [J].
Hazzan, Tarek ;
Eberle, Juergen ;
Worm, Margitta ;
Babina, Magda .
CELLS, 2019, 8 (08)
[45]   AUTOANTIBODIES AGAINST THE HIGH-AFFINITY IGE RECEPTOR AS A CAUSE OF HISTAMINE-RELEASE IN CHRONIC URTICARIA [J].
HIDE, M ;
FRANCIS, DM ;
GRATTAN, CEH ;
HAKIMI, J ;
KOCHAN, JP ;
GREAVES, MW .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (22) :1599-1604
[46]   Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients [J].
Jorg, L. ;
Pecaric-Petkovic, T. ;
Reichenbach, S. ;
Coslovsky, M. ;
Stalder, O. ;
Pichler, W. ;
Hausmann, O. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (02) :196-204
[47]   Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety [J].
Kahveci, M. ;
Soyer, O. ;
Buyuktiryaki, B. ;
Sekerel, B. E. ;
Sahiner, U. M. .
ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2020, 48 (04) :368-373
[48]   Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria [J].
Kaplan, A. P. ;
Gimenez-Arnau, A. M. ;
Saini, S. S. .
ALLERGY, 2017, 72 (04) :519-533
[49]   Pathogenesis of chronic urticaria [J].
Kaplan, A. P. ;
Greaves, M. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (06) :777-787
[50]   Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria [J].
Kaplan, Allen ;
Ferrer, Marta ;
Bernstein, Jonathan A. ;
Antonova, Evgeniya ;
Trzaskoma, Benjamin ;
Raimundo, Karina ;
Rosen, Karin ;
Omachi, Theodore A. ;
Khalil, Sam ;
Zazzali, James L. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) :474-481